BioMaxima

BioMaxima Supply Chain

Supply Chain of BioMaxima (BMX.WA) as of Oct 17, 2026.

Supply Chain

-

Last updated:

Supply chains in stock corporations are essential components of business infrastructure and play a crucial role in value creation and competitiveness. These supply chains encompass all steps from raw material procurement and production to the delivery of finished products to the end customer.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioMaxima Stock analysis

What does BioMaxima do? BioMaxima SA is a company based in Lublin, Poland, operating within the Health Care sector, specifically in the Health Care industry. The company went public via an IPO on June 8, 2010, and is listed under the ticker BMX.WA with ISIN PLBIOMX00015. BioMaxima SA specializes in biotechnology and laboratory diagnostics, manufacturing and distributing reagents and equipment for laboratory diagnosis. The company produces in vitro diagnostic reagents and offers a range of products including diagnostic reagents and analyzers for clinical biochemistry, rapid tests and readers for detecting infectious diseases, cancer markers, cardiac markers, and drugs of abuse, urine analysis systems, hematology analyzers and reagents, ion-selective analyzers and reagents, reagents and immunological analyzers for cardiac markers, glucometers, and analyzers for gasometric and critical blood parameters tests. BioMaxima SA supplies hospitals and laboratories across Poland, Lithuania, Latvia, Romania, and France. The company merged with its wholly owned subsidiary Cebo Sp z o o on March 20, 2014. The company's website is https://biomaxima.com/. BioMaxima is one of the most popular companies on Eulerpool.

All Key Metrics — BioMaxima